Traws Pharma, Inc.
TRAW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001130598
No open-market purchases or sales by Traws Pharma, Inc. insiders were filed in the last 90 days; 34 institutions reported holding it in 13F filings for Q2 2026, worth $5.19M in total; no superinvestor holds it.
Holders of 5% or more of TRAW
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Traws Pharma, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| OrbiMed Advisors LLC | 13D/A | 19.90%760.8K shares | – | Jan 29, 20251 filing | Jan 29, 2025 | SEC |
| Perceptive Advisors LLC | 13G/A | 9.99%886.9K shares | 0.00 ppfrom 9.99% | Jan 8, 20253 filings | Nov 14, 2025 | SEC |
| Ikarian Capital, LLC | 13G/A | 9.99%589.5K shares | 0.00 ppfrom 9.99% | Feb 14, 20252 filings | May 15, 2025 | SEC |
| Ayrton Capital LLC | 13G | 9.90%403.6K shares | New | Feb 13, 20251 filing | Feb 13, 2025 | SEC |
| Alyeska Investment Group, L.P. | 13G | 9.90%302.3K shares | New | Feb 14, 20251 filing | Feb 14, 2025 | SEC |
| Squadron Capital Management LLC | 13G/A | 8.40%591.0K shares | +2.40 ppfrom 6.00% | Sep 19, 20252 filings | Nov 14, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
12 Schedule 13D and 13G filings on Traws Pharma, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 14, 20254:00 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 9.99%886.9K shares | 0.00 ppfrom 9.99% | Sep 30, 2025 | SEC |
| Nov 14, 20252:29 PM ET | Squadron Capital Management LLCand 3 others | 13G/A | 8.40%591.0K shares | +2.40 ppfrom 6.00% | Sep 30, 2025 | SEC |
| Nov 13, 20259:07 AM ET | Adage Capital Management, L.P.and 2 others | 13G/A | 4.67%330.0K shares | −1.83 ppfrom 6.50%Below 5% | Sep 30, 2025 | SEC |
| Sep 19, 20253:04 PM ET | Squadron Capital Management LLCand 3 others | 13G | 6.00%420.5K shares | New | Sep 12, 2025 | SEC |
| May 15, 20255:26 PM ET | Ikarian Capital, LLCand 1 other | 13G/A | 9.99%589.5K shares | 0.00 ppfrom 9.99% | Mar 31, 2025 | SEC |
| May 15, 20254:30 PM ET | Perceptive Advisors LLCand 2 others | 13G/A | 9.99%545.2K shares | +0.09 ppfrom 9.90% | Mar 31, 2025 | SEC |
| May 12, 20259:02 AM ET | Adage Capital Management, L.P.and 2 others | 13G | 6.50%330.0K shares | New | Mar 31, 2025 | SEC |
| Feb 14, 20254:22 PM ET | Alyeska Investment Group, L.P.and 2 others | 13G | 9.90%302.3K shares | New | Dec 31, 2024 | SEC |
| Feb 14, 20251:18 PM ET | Ikarian Capital, LLCand 1 other | 13G | 9.99%394.3K shares | New | Dec 31, 2024 | SEC |
| Feb 13, 20251:07 PM ET | Ayrton Capital LLCand 2 others | 13G | 9.90%403.6K shares | New | Dec 31, 2024 | SEC |
| Jan 29, 20256:42 PM ET | OrbiMed Advisors LLCand 1 other | 13D/A | 19.90%760.8K shares | – | Dec 31, 2024 | SEC |
| Jan 8, 20259:28 PM ET | Perceptive Advisors LLCand 2 others | 13G | 9.90%386.6K shares | New | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Traws Pharma, Inc. shares.
No Form 144 notices for Traws Pharma, Inc. are on file.